Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive OfficerBusiness Wire • 09/20/22
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx SummitBusiness Wire • 09/16/22
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business ProgressBusiness Wire • 08/08/22
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of DirectorsBusiness Wire • 07/26/22
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare ConferenceBusiness Wire • 07/19/22
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research ConferenceBusiness Wire • 07/15/22
Does Scholar Rock Holding Corporation (SRRK) Have the Potential to Rally 246% as Wall Street Analysts Expect?Zacks Investment Research • 07/11/22
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)Business Wire • 07/01/22
How Much Upside is Left in Scholar Rock Holding Corporation (SRRK)? Wall Street Analysts Think 394%Zacks Investment Research • 06/24/22
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)Business Wire • 06/17/22
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA ConferenceBusiness Wire • 06/09/22
Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 413%: Read This Before Placing a BetZacks Investment Research • 06/08/22
Down 43.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Scholar Rock Holding Corporation (SRRK)Zacks Investment Research • 05/20/22
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic PrioritiesBusiness Wire • 05/16/22
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society CongressBusiness Wire • 04/21/22
Scholar Rock Holding Corporation (SRRK) Stock Jumps 9.2%: Will It Continue to Soar?Zacks Investment Research • 03/24/22
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual MeetingBusiness Wire • 03/22/22
Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceBusiness Wire • 03/13/22
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/07/22
Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business ProgressBusiness Wire • 03/07/22